Cadila zooms 9% on USFDA nod for Cilexetil Tablets

Free Stock Tips

IF YOU ARE WILLING FOR A RISK-FREE TRADE SO YOU CAN CHOOSE US FOR A GOOD RECOMMENDATIONS AND LET YOURSELF TO TAKE A GOOD ADVANTAGE FROM THE INDIAN STOCK MARKET JUST CLICK HERE AND JOIN US FOR FREE >> http://www.ripplesadvisory.com/free-trial.php

Shares of Cadila Healthcare rallied nearly 9 per cent on the Bombay Stock Exchange after the drug maker said that its subsidiary Zydus has received final approval from the USFDA for Candesartan Cilexetil Tablets. Following the announcement, shares of the company gained as much as 8.91 per cent to hit an intra-day high of Rs 503.90 apiece on the Bombay Stock Exchange.

The stocks were currently trading at Rs 496.10 against the previous close price of Rs 462.50. In a similar fashion, shares of the company were trading 7.46 per cent higher at Rs 497.15 apiece on the National Stock Exchange. 

Meanwhile, the broader benchmark BSE Sensex was trading at 31,576.89, up 8.88 points, or 0.03 per cent, at 12:20 hours.

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

सकारात्मक वैश्विक रुझानों के सहारे बाजार में मजबूती, निफ्टी 10,900 के ऊपर

11-year data suggests bears control D-Street in September; can bulls defy odds?